UCSF Brain Tumor Center Clinical Trials
Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors.
-
Recruiting
- Pediatrics
- On Hold
Conditions
Glioblastoma
This multicenter phase 2 immunotherapy trial will evaluate the combination of two immune checkpoint inhibitors, nivolumab and relatlimab, in patients with newly diagnosed isocitrate dehydrogenase (IDH)-wild-type glioblastoma.
Conditions
Glioma
Glioblastoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Oligodendroglioma
This is a phase 1 immunotherapy trial for patients with recurrent high-grade gliomas designed to evaluate the safety and biological activity of the gene therapy, SRN-101, administered prior to planned surgical resection.
Conditions
Glioma
Glioblastoma
This is a phase 0/I exploratory study to evaluate the safety and toxicity profile of anti-TIGIT AB154 in combination with anti-PD-1 AB122 in patients with recurrent glioblastoma.
Conditions
Glioma
Glioblastoma
This single-center Phase I/Ib study in recurrent glioblastoma (GBM) aims to establish a recommended phase 2 dose of the mTOR inhibitor RMC-552 in GBM participants as well as to evaluate safety and antitumor effect of this drug.
Conditions
Glioblastoma
Glioma
This is an open-label phase I/II clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of the drug TNG908 in patients with MTAP-deleted advanced or metastatic solid tumors.
Conditions
Glioma
Glioblastoma
This is a first-in-human phase 1 study to assess the safety and feasibility of using an IV infusion of E-SYNC T cells to treat patients with EGFRvIII-mutated glioblastoma (GBM).
Conditions
Glioma
Glioblastoma
The purpose of this prospective, self-controlled study is to evaluate the safety and
effectiveness of using focused ultrasound in adults with glioblastoma to increase temporarily the permeability of the blood-brain barrier, allowing increased passage of circulating free DNA for sampling and analysis.
Conditions
Glioma
Astrocytoma
Glioblastoma
This phase I trial will evaluate an individualized treatment approach, based on the results of the UCSF 500 Cancer Gene Panel, for patients with surgically resectable recurrent glioblastoma.
Conditions
Glioma
Glioblastoma
This is a phase I/II trial that aims to to establish a safe and effective dose of albumin-bound paclitaxel, to demonstrate that the opening of the blood-brain barrier increases chemotherapy concentration in the tumor, and to estimate how effective this treatment is in reducing the tumor burden and prolonging life.
Conditions
Glioblastoma
Summary
This is a prospective, randomized, placebo-controlled, multi-center study of patients with newly diagnosed glioblastoma to evaluate a peptide vaccine (SurVaxM) in emulsion with Montanide given together with locally administered sargramostim plus adjuvant oral temozolomide (Arm A) versus
Conditions
Glioma
Astrocytoma
Glioblastoma
Isocitrate Dehydrogenase (IDH)-Mutant Astrocytoma
Chordoma
Schwannoma (grade 1)
Craniopharyngioma
Oligodendroglioma
Meningioma
Pituitary Tumor
This observational study will collect data to better understand our patient population and their behavior around cannabis, as well as clinical outcomes that might be linked to the consumption of cannabis.
Conditions
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Glioma
Glioblastoma
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Natural killer (NK) cells are immune cells that recognize and get rid of abnormal cells in the body, including tumor cells and cells infected by viruses. NK cells have been shown to kill different types of cancer, including brain tumors in laboratory settings.